GSK Class Action News: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Involving GSK PLC
SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
GSK to grow Massachusetts work force with move from Maryland
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
GSK, gold miners shares push Britain's FTSE 100 higher
UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 ...
GSK is emerging from its long convalescence
Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share ...